Patents Examined by Prema M Mertz
  • Targeted immunotolerance
    Patent number: 11466068
    Abstract: Methods and compounds for conferring site-specific or local immune privilege.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: October 11, 2022
    Assignee: Pandion Operations, Inc.
    Inventors: Joanne L. Viney, Nathan Higginson-Scott
  • Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins
    Patent number: 11466061
    Abstract: The present invention relates to methods and compositions for treating and/or preventing a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, methods and compositions for diagnosis, prognosis or treatment monitoring of a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, and methods and compositions for identifying a modulator of the IFP35 family of proteins, including IFP35 and NMI.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: October 11, 2022
    Inventor: Yingfang Liu
  • IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same
    Patent number: 11459367
    Abstract: A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein includes first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted. When the heterodimeric Fc-fused protein is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: October 4, 2022
    Assignees: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Kyung-Mi Lee, Seon Ah Lim, Yong Sung Kim, Ye Jin Kim
  • Biopharmaceutical compositions
    Patent number: 11459384
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: October 4, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Activatable interleukin 12 polypeptides and methods of use thereof
    Patent number: 11453710
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: September 27, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Methods and compositions for the treatment of ocular diseases and disorders
    Patent number: 11447568
    Abstract: Compositions and methods for the treatment of an ocular disease or disorder are disclosed.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 20, 2022
    Assignee: Lankenau Institute for Medical Research
    Inventors: Arturo Bravo-Nuevo, George C. Prendergast
  • Compositions and methods for treating granulomatosis with polyangiitis
    Patent number: 11446366
    Abstract: The present specification disclose methods and uses for the treatment of a vasculitic syndrome. The disclosed methods comprise administering a composition comprising a Proteinase 3 (PR3) inhibitor to a patient in need thereof. Also disclosed are compositions comprising a PR3 inhibitor disclosed herein for use in the treatment of a vasculitic syndrome as well as use of a composition comprising a PR3 inhibitor disclosed herein in the treatment of a vasculitic syndrome. The present specification also discloses use of a composition comprising a PR3 inhibitor disclosed herein in the manufacture of a medicament for the treatment of a vasculitic syndrome.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 20, 2022
    Assignee: Canem Holdings, LLC
    Inventor: Adam Haeberle
  • Method for diagnosing and treating fibromyalgia
    Patent number: 11442068
    Abstract: The invention provides methods, kits and reagents for diagnosing fibromyalgia (FM) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of FM in the individual.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 13, 2022
    Assignee: EPICGENETICS, INC.
    Inventor: Bruce S. Gillis
  • Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody
    Patent number: 11440964
    Abstract: The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: September 13, 2022
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove
  • Anti-BCMA heavy chain-only antibodies
    Patent number: 11434299
    Abstract: Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 6, 2022
    Assignee: TeneoBio, Inc.
    Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
  • Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein
    Patent number: 11434270
    Abstract: Provided is polypeptide which derives from wild type TNF a and inhibits necrocytosis. The polypeptide contains 10-200 amino acid residues and a sequence QLVVPSE. Also provided is a pharmaceutical composition containing polypeptide. The polypeptide and the pharmaceutical composition containing the polypeptide are capable of inhibiting necrocytosis, thereby being used for treating inflammatory diseases.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: September 6, 2022
    Assignee: SHANGHAI JW INFLINHIX CO., LTD.
    Inventors: Shisong Jiang, Wenshu Lu
  • NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents
    Patent number: 11433122
    Abstract: Natural killer (NK)-lysin peptides from chicken, bovine and human species are used as an antimicrobial or antiviral agent alone or in combination with other agents. A pharmaceutical composition comprising NK-lysin peptides was effective against Rotavirus and various gram-negative and gram-positive bacteria that were tested. Combinations of NK-lysin peptides plus silver nanoparticles or IL-2 were also effective against Salmonella typhimurium. Treatment with the NK-lysin peptides repressed ?-lactam-resistance genes (CTX-M-1, CTX-M-8 and CTX-M-9) in bacterial species tested and thus can be used to augment treatment with ?-lactams and increase bacterial sensitivity to this important class of antibiotics.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: September 6, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Maged Mostafa Mahmoud, Haitham A. Yacoub, Ahmed M. Al-Hejin, Turki Abujaml, Sherif Abd-Elmaksoud
  • Methods and compositions for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
    Patent number: 11426449
    Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: August 30, 2022
    Assignee: REPONEX PHARMACEUTICALS A/S
    Inventor: Lars Heslet
  • High concentration formulations of anti-CSF1 and anti-CSF1R antibodies
    Patent number: 11419822
    Abstract: Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: August 23, 2022
    Assignee: AmMax Bio, Inc.
    Inventors: Laman Alani, Chung-Chiang Hsu, Aihua Zhu, Kirk William Johnson, Michael Huang
  • Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock
    Patent number: 11413333
    Abstract: The present invention relates to a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock. The inducer of SIRT1 expression can remarkably reduce the mortality caused by sepsis or septic shock by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines. Therefore, the inducer of SIRT1 expression is useful for preventing or treating sepsis or septic shock.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 16, 2022
    Inventors: Myung Kwan Han, Chae Hwa Yoo, Eun Kyung Song, Seung Ok Lee
  • Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
    Patent number: 11407814
    Abstract: Provided are multi-functional and multi-valent fusion polypeptides comprising an interleukin polypeptide and two or more TGF? ligand-binding polypeptides. The compositions and methods provided herein are useful in the application of preventing tumorigenesis and treating cancer.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: August 9, 2022
    Assignee: CURA THERAPEUTICS, INC.
    Inventor: Claudia Ania Penafuerte Diaz
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11407813
    Abstract: The present disclosure pertains compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: August 9, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li, Matthew Franklin
  • QTY FC fusion receptor proteins
    Patent number: 11401320
    Abstract: The present invention is directed to QTY CCR9 and CXCR2 variant Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: August 2, 2022
    Assignees: Massachusetts Institute of Technology, Avalong GloboCare Corp.
    Inventors: Shuguang Zhang, David Jin, Rui Qing, Uwe Sleytr
  • Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
    Patent number: 11395853
    Abstract: A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent loaded-carrier provides controlled delivery of the therapeutic agent under conditions suitable for recruiting regulatory T cells to an ocular region of interest or inducing regulatory T cells in an ocular region of interest.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: July 26, 2022
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Steven R. Little, Michelle L. Guaragno, Andrew J. Glowacki, Morgan V. Fedorchak, Stephen C. Balmert
  • Bispecific antibodies against plasma kallikrein and Factor XII
    Patent number: 11390687
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: July 19, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman